Table 4.
Relationship between prescription of each different category of medication and long‐term outcomes
| Mortality | MI | Mortality or MI | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Event Rate | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Event Rate1 | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | Event Rate | Unadjusted HR (95% CI) | Adjusted HR (95% CI) | |
| β‐Blocker | 25 vs 27 | 0.97 (0.84‐1.11) | 0.76 (0.66‐0.88) | 7 vs 5 | 1.37 (1.01‐1.86) | 1.20 (0.87‐1.64) | 29 vs 30 | 1.02 (0.89‐1.16) | 0.82 (0.72‐0.94) |
| CCB | 28 vs 23 | 1.26 (1.13‐1.39) | 1.16 (1.04‐1.29) | 7 vs 6 | 1.17 (0.95‐1.44) | 1.04 (0.84‐1.29) | 32 vs 27 | 1.23 (1.12‐1.36) | 1.13 (1.03‐1.25) |
| Long‐acting nitrates | 29 vs 23 | 1.35 (1.22‐1.51) | 1.20 (1.08‐1.34) | 8 vs 6 | 1.40 (1.13‐1.73) | 1.23 (0.99‐1.53) | 34 vs 27 | 1.34 (1.21‐1.48) | 1.19 (1.07‐1.32) |
| Ranolazine | 35 vs 25 | 1.51 (0.96‐2.37) | 1.29 (0.82‐2.04) | 5 vs 7 | 0.85 (0.27‐2.65) | 0.73 (0.23‐2.28) | 38 vs 29 | 1.38 (0.90‐2.12) | 1.19 (0.77‐1.83) |
Abbreviations: CCB, calcium channel blocker; CI, confidence interval; HR, hazard ratio; MI myocardial infarction.
1
5‐year unadjusted cumulative incidence rate (%).